“Independent promises” – Australia’s Full Federal Court provides further guidance on exclusive licences
On 9 September 2016, the Full Federal Court of Australia delivered its judgment in Actavis Pty Ltd v Orion Corporation [2016] FCAFC 121 (Actavis). The proceedings concerned the infringement/revocation of a patent for Stalevo, Novartis’ 3-in-1 Parkinson’s disease drug. A related issue was whether Novartis Pharma AG (Novartis) was the exclusive licensee of Orion’s 765932…